Skin allografts generate an enhanced production of histamine and histamine-producing cell-stimulating factor (HCSF) by spleen cells in response to T cell mitogens.
In response to T cell mitogens, spleen cells produce a large amount of histamine, whereas no or a slight increase is observed after B cell mitogen stimulation. This increased histamine production results from the effect of a factor having all the characteristics of HCSF (histamine-producing cell-stimulating factor) already described in secondary MLC supernatant. This factor is produced by Thy-1, 2, Lyt-1, 2-positive cells. Spleen cell cultures derived from skin-allografted mice during rejection produce more histamine in response to T cell mitogens than do spleen cells from normal or syngeneic grafted mice. Such a phenomenon is not observed in response to B cell mitogens. A striking association is found between enhanced histamine synthesis and skin allograft rejection. This phenomenon results from a) a five to 10-fold increase in HCSF production by allograft recipient spleen cells in response to T cell mitogens, and b) an increase in HCSF sensitivity of these spleen cells.
D000818:Animals; D000954:Antigens, Surface / Q000276:immunology; D000961:Antilymphocyte Serum / Q000494:pharmacology; D001853:Bone Marrow / Q000276:immunology; D001854:Bone Marrow Cells; D003208:Concanavalin A / Q000494:pharmacology; D006636:Histamine Release; D007519:Isoantigens / Q000276:immunology; D008213:Lymphocyte Activation; D008222:Lymphokines / Q000096:biosynthesis*; D051379:Mice; D008810:Mice, Inbred C57BL; D008811:Mice, Inbred DBA; D010835:Phytohemagglutinins / Q000494:pharmacology; D016038:Skin Transplantation; D013154:Spleen / Q000166:cytology / Q000276:immunology; D013601:T-Lymphocytes / Q000276:immunology*; D018800:Thy-1 Antigens
D000954:Antigens, Surface; D000961:Antilymphocyte Serum; D007519:Isoantigens; D008222:Lymphokines; D010835:Phytohemagglutinins; D018800:Thy-1 Antigens; D003208:Concanavalin A